Show simple item record

dc.contributor.authorKirkham, Bruce
dc.contributor.authorNash, Peter
dc.contributor.authorNavarra, Sandra
dc.contributor.authorQuebe-Fehling, Erhard
dc.contributor.authorGaillez, Corine
dc.contributor.authorSastre, Carlos
dc.contributor.authorMease, Philip
dc.description.abstractBackground/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed to evaluate the impact of biologics on resolution of dactylitis are limited.3 We report results of a post hoc analysis evaluating the effect of secukinumab (SEC) on PsA patients with dactylitis, from the FUTURE 5 trial (NCT02404350). Methods: FUTURE 5 is a randomized, double-blinded, placebo-controlled, 2-year phase 3 trial in patients with active PsA. Patients (aged ≥18 years) were randomized 2:2:2:3 to s.c. SEC 300 mg or 150 mg with loading dose (LD), 150 mg without loading dose (NL) or placebo. All groups received SEC or placebo at baseline, weeks (wks) 1, 2 and 3 and then every 4 wks from Wk 4. Exploratory efficacy analysis at Wks 16 and 52 included time to resolution of dactylitis by dactylitis severity, proportion of patients with resolution of dactylitis, ACR 20/50 response and Psoriasis Area and Severity Index (PASI) 90. Results: Of the 996 patients in the trial, 389 (39%) had dactylitis (SEC 150 mg NL [N=103], 150 mg LD [N=80], 300 mg LD [N=82], and placebo [N=124]). The mean (SD) tender joint count, swollen joint count and dactylitis count at baseline was: 24.0 (17.0), 14.5 (11.4) and 4.1 (4.16) and 19.1 (14.8), 9.5 (8.5) and 0, respectively, in patients with (N=389) and without (N=607) dactylitis at baseline. Higher presence of enthesitis, hsCRP and skin disease were also observed in the dactylitis subset. Median time to resolution of dactylitis (days) [95% CI] in patients on SEC 150 mg NL, 150 mg LD, and 300 mg LD, was 85 [61.0, 113.0], 85 [57.0, 119.0] and 57 [30.0, 85.0], respectively. A higher proportion of SEC treated patients achieved resolution of dactylitis, ACR 20/50 and PASI90 responses vs. placebo at Wk16 with further improvements through Wk 52 (Table 1). Resolution of dactylitis based on the number of dactylitis count at baseline (≤2 and ≥3) are shown in Table 2. SEC 300 mg LD was associated with a faster time to resolution of dactylitis and higher ACR50 and PASI90 responses compared to SEC 150 mg. Conclusion: A higher level of disease burden was observed in patients with dactylitis compared to patients without dactylitis. SEC 300 mg was associated with a faster time to resolution of dactylitis, higher resolution of dactylitis irrespective of severity and higher responses on skin and joints.en_US
dc.relation.ispartofconferencenameACR Convergence 2020en_US
dc.relation.ispartofconferencetitleArthritis & Rheumatologyen_US
dc.subject.fieldofresearchClinical Sciencesen_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.titleSecukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trialen_US
dc.typeConference outputen_US
dc.type.descriptionE3 - Conferences (Extract Paper)en_US
dcterms.bibliographicCitationKirkham, B; Nash, P; Navarra, S; Quebe-Fehling, E; Gaillez, C; Sastre, C; Mease, P, Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial, ARTHRITIS & RHEUMATOLOGY, 2020, 72 (S10), pp. 2783-2785en_US
gro.hasfulltextNo Full Text
gro.griffith.authorNash, Peter

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record